Communicating contraceptive effectiveness: A randomized controlled trial to inform a World Health Organization family planning handbook

American Journal of Obstetrics and Gynecology

Volumn 195, Issue 1, 2006, Pages 85-91

  Steiner, Markus J ^a   Trussell, James ^b   Mehta, Neha ^a   Condon, Sean ^a   Subramaniam, Sumathi ^c   Bourne, Deborah ^d  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c Hope Enterprises Ltd ^*

^d Hope Enterprises Ltd   (Jamaica)

Author keywords

Contraception; Contraceptive counseling; Decision aids; Informed choice

Indexed keywords

CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FAMILY PLANNING; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 33745262593     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.12.053     Document Type: Article

References (16)

1. Grady W.R., Klepinger D.H., and Nelson-Wally A. Contraceptive characteristics: the perceptions and priorities of men and women. Fam Plann Perspect 31 (1999) 168-175
2. Little P., Griffin S., Kelly J., Dickson N., and Sadler C. Effect of educational leaflets and questions on knowledge of contraception in women taking the combined contraceptive pill: randomised controlled trial. BMJ 316 (1998) 1948-1952
3. Edwards J.E., Oldman A., Smith L., McQuay H.J., and Moore R.A. Women's knowledge of, and attitudes to, contraceptive effectiveness and adverse health effects. Br J Fam Plann 26 (2000) 73-80
4. Steiner M.J., Dalebout S., Condon S., Dominik R., and Trussell J. Understanding risk: a randomized controlled trial of communicating contraceptive effectiveness. Obstet Gynecol 102 (2003) 709-717
5. Snow R., Garcia S., Kureshy N., Sadana R., Singh S., Becerra-Valdivia M., et al. Attributes of contraceptive technology: women's preferences in seven countries. Reprod Health Matters (1997) special issue:36-44
6. Sadana R., and Snow R. Balancing effectiveness, side-effects and work: women's perceptions and experiences with modern contraceptive technology in Cambodia. Soc Sci Med 49 (1999) 343-358
7. Garcia S., Snow R., and Aitken I. Preferences for contraceptive attributes: voices of women in Ciudad Juarez, Mexico. Int Fam Plann Perspect 23 (1997) 52-58
8. O'Connor A.M., Legare F., and Stacey D. Risk communication in practice: the contribution of decision aids. BMJ 327 (2003) 736-740
9. O'Connor A.M., Stacey D., Entwistle V., Llewellyn-Thomas H., Rovner D., Holmes-Rovner M., et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2003) (2):CD001431
10. Chewning B., Mosena P., Wilson D., Erdman H., Potthoff S., Murphy A., et al. Evaluation of a computerized contraceptive decision aid for adolescent patients. Patient Educ Couns 38 (1999) 227-239
11. Trussell J. Contraceptive efficacy. In: Hatcher R.A., Trussel J., Stewart F., Nelson A.L., Cates Jr. W., Guest F., et al. (Eds). Contraceptive technology. 18th ed. (2004), Ardent Media Inc, New York 773-845
12. Trussell J. Contraceptive failure in the United States. Contraception 70 (2004) 89-96
13. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357 (2001) 1191-1194
14. Grisaffe D.B., and Shellabarger S. Consumer comprehension of efficacy data in four experimental over-the-counter label conditions. Drug Inf J 31 (1997) 937-961
15. European Commission. A guideline on the readability of the label and package leaflet of medical products for human use. European Commission Pharmaceutical Committee; Brussels: 1998. Available at: http://pharmacos.eudra.org/F2/eudralex/vol-2/C/gl981002.pdf. Accessed 24 January 2006.
16. Berry D.C., Raynor D.K., Knapp P., and Bersellini E. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 26 (2003) 1-11